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Aim Describe the distinguishing features of heart failure (HF) patients with reduced ejection fraction (HFrEF) in the
VICTORIA (Vericiguat Global Study in Patients with Heart Failure with Reduced Ejection Fraction) trial.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
Key background characteristics were evaluated in 5050 patients randomized in VICTORIA and categorized into three
cohorts reflecting their index worsening HF event. Differences within the VICTORIA population were assessed
and compared with PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global
Mortality and Morbidity in Heart Failure) and COMMANDER HF (A Study to Assess the Effectiveness and Safety of
Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction, or Stroke in Participants with Heart Failure and
Coronary Artery Disease Following an Episode of Decompensated Heart Failure). VICTORIA patients had increased
risk of mortality and rehospitalization: New York Heart Association class (40% class III), atrial fibrillation (45%),
diabetes (47%), hypertension (79%) and mean estimated glomerular filtration rate of 61.5 mL/min/1.73 m2. Baseline
standard of HF care was very good: 60% received triple therapy. Their N-terminal pro-B-type natriuretic peptide
was 3377 pg/mL [interquartile range (IQR) 1992–6380]. Natriuretic peptides were 30% higher level in the 67%
patients with HF hospitalization <3 months, compared to those within 3–6 months of HF hospitalization and those
randomized after recent outpatient intravenous diuretic therapy. Overall the median MAGGIC (Meta-Analysis Global
Group in Chronic Heart Failure) risk score in VICTORIA was 23 (IQR 18–27) as compared to the MAGGIC risk
score in PARADIGM-HF of 20 (IQR 16–24).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusions VICTORIA comprises a broadly generalizable high-risk population of three unique clinical strata of worsening chronic
HFrEF despite very good HF therapy. VICTORIA will establish the role of vericiguat, a soluble guanylate cyclase
stimulator, in HFrEF.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Soluble guanylate cyclase • Cyclic guanosine monophosphate • Heart failure with reduced ejection
fraction • Clinical trial
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Fax: +1 780 192-0613, Email: paul.armstrong@ualberta.ca
†Listed in online supplementary Appendix S1.
..
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
VICTORIA heart failure baseline features 1597
Introduction
Despite recent advances in the management of patients with heart
failure (HF) with reduced ejection fraction (HFrEF), this disor-
der continues to extract considerable penalties as expressed by
impaired quality of life coupled with excess morbidity and mor-
tality. This is especially apparent in those HF patients who – even
after initial stabilization – experience further worsening of their
HF despite receiving best contemporary standard of care.1 More-
over, the contemporary rise in longevity of the overall population,
coupled with continuing advances in the management of coronary
artery and other cardiovascular (CV) diseases, prioritizes a search
for novel HF therapies.
Based on experimental and initial clinical investigations, one new
pathway that appears promising relates to the modulation of nitric
oxide (NO)–soluble guanylate cyclase (sGC) pathway that gener-
ates cyclic guanosine monophosphate (cGMP), essential for both
normal cardiac and vascular function.2,3 In HF patients, there is
reduced NO bioavailability resulting in a relative sGC deficiency
and reduced generation of cGMP.2 Although strategies that include
substitution of exogenous NO by nitrates and inhibition of cGMP
degradation by phosphodiesterase inhibitors have been under-
taken, neither have proven to provide lasting benefit.2,3 Because
sGC plays a key role in generating cGMP, vericiguat was developed
as a potential novel addition to the HF treatment armamentarium.
Vericiguat has a dual mechanism by which it increases cGMP in
that it directly stimulates sGC through a binding site independent
of NO and also sensitizes sGC to endogenous NO by stabilizing
the NO–sGC binding site.3,4
The VICTORIA (Vericiguat Global Study in Subjects with Heart
Failure with Reduced Ejection Fraction) trial completed enrolment
of 5050 patients in December 2018. VICTORIA was designed
to capture a HF population at increased risk for mortality and
rehospitalization that represents a major continuing therapeutic
challenge.5 The support for this design was drawn from the phase
IIb dose-finding study SOCRATES-REDUCED (Soluble Guanylate
Cyclase Stimulator in Heart Failure with Reduced Ejection Fraction
Study) of high-risk worsening HF patients in whom vericiguat
reduced N-terminal pro-B-type natriuretic peptide (NT-proBNP)
levels in the highest dose group.6
The purpose of this communication is to describe the distin-
guishing features of this unique population and compare their base-
line features with the PARADIGM-HF (Prospective comparison of
ARNI with ACEI to Determine Impact on Global Mortality and
morbidity in Heart Failure) and COMMANDER HF (A Study to
Assess the Effectiveness and Safety of Rivaroxaban in Reducing the
Risk of Death, Myocardial Infarction, or Stroke in Participants with
Heart Failure and Coronary Artery Disease Following an Episode
of Decompensated Heart Failure) trials in order to provide a con-
textual framework with this HFrEF population.7,8
Methods
The VICTORIA protocol has been described previously.5 In brief, this
trial assessed whether vericiguat was superior to placebo in increas-



















































































.. Table 1 VICTORIA trial inclusion criteria
• Ejection fraction <45% assessed within 12 months prior to
randomization
• Elevated natriuretic peptide levels within 30 days prior to
randomization; for patients in sinus rhythm BNP ≥300 pg/mL
and NT-proBNP ≥1000 pg/mL; for those in atrial fibrillation
BNP ≥500 pg/mL and NT-proBNP ≥1600 pg/mLa
• Prior HF hospitalization within 6 months (those >3 months
limited to 20%) or outpatient IV diuretic therapy for HF within
3 months prior to randomization
BNP, B-type natriuretic peptide; HF, heart failure; IV, intravenous; NT-proBNP,
N-terminal pro-B-type natriuretic peptide.
aFor those subjects receiving sacubitril/valsartan, NT-proBNP criteria will be
applied.
death or HF hospitalization in patients with HFrEF receiving opti-
mal background standard of HF care. The cardinal entry criteria are
summarized in Table 1 and included an ejection fraction (EF) <45%
within 12 months prior to randomization and elevated natriuretic pep-
tide (NP) levels adjusted for the presence of atrial fibrillation. Three
distinct cohorts (as reported by sites) were included to represent
the evolution of patients with prior stable HF but subsequent symp-
tomatic worsening: <3 months, 3–6 months after hospitalization, as
well those receiving intravenous (IV) diuretic therapy, without hospi-
talization, within the prior 3 months. No more than 20% of subjects
were to be randomized with a qualifying HF hospitalization >3 months
prior to randomization. The inclusion criteria were intended to be
broad. Hence, up to 15% of subjects were intended to have an esti-
mated glomerular filtration rate (eGFR) in the 15 to 30 mL/min/1.73 m2
range, and all received optimized standard of care: inclusion of patients
receiving sacubitril/valsartan background therapy, where available, was
encouraged. Enrolment of 5050 patients, across 42 countries, and
categorized into five pre-specified geographic regions was completed
in 26 months, which was earlier than projected and approximately
3 months ahead of schedule in this endpoint-driven trial (782 clini-
cal events committee (CEC)-confirmed CV deaths required) and it
is anticipated that at least 1561 patients will experience a compos-
ite primary endpoint. Based on an expected CV death event rate
of 11% at 12 months in the placebo group, and an assumed rela-
tive risk reduction of 20% in the vericiguat group, a power of 80%
will be achieved. The study will continue to accrue endpoints over
approximately 35 months with a median follow-up of 12 months. The
last patient last visit was achieved on 2 September 2019 and the
primary results are anticipated to be available in the first quarter
of 2020.
Statistical analysis
Patient characteristics available at baseline, including concomitant
medications, are presented as counts (percentages) for categorical
variables and as medians (25th, 75th percentiles) for continuous
variables. The proportion of missing values was reported for the NPs
available at screening and the MAGGIC (Meta-Analysis Global Group
in Chronic Heart Failure) risk score.9 The MAGGIC risk score was
adapted according to the method described by the PARADIGM-HF
investigators,10 and was reported in patients with available data in
the VICTORIA trial. The following factors comprised the MAGGIC
risk score: age, EF, New York Heart Association (NYHA) class, serum
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 VICTORIA patients screening summary
Patients screened 6899
Patients randomized 5050 (73.2%)
Patients not randomized 1849 (26.8%)
Reasons for non-randomization
Inclusion criteria not met
Have BNP or NT-proBNP levels within range within 30 days prior to randomization 1080 (58.4%)
Provide written informed consent for the trial 197 (10.7%)
Have a history of chronic HF (NYHA class II–IV) 74 (4.0%)
Have LVEF <45% assessed within 12 months prior to randomization 64 (3.5%)
Have a previous HF hospitalization within 6 months prior to randomization or IV diuretic treatment for HF (without
hospitalization) within 3 months prior to randomization
63 (3.4%)
Meet one of reproductive criteria 26 (1.4%)
Inability to provide informed consent 23 (1.2%)
Exclusion criteria present
Clinically unstable at the time of randomization (exclusion) 265 (14.3%)
Medical disorder, condition, or history impairing ability to participate 81 (4.4%)
Concurrent or anticipated use of long-acting nitrates or NO donors 37 (2.0%)
eGFR <15 mL/min/1.73 m2 or chronic dialysis 19 (1.0%)
Known allergy or sensitivity to any sGC stimulator 14 (0.8%)
Primary valvular heart disease requiring surgery or intervention, or within 3 months after valvular surgery or intervention 13 (0.7%)
ACS (unstable angina, NSTEMI, STEMI, CABG, or PCI) 18 (1.0%)
Miscellaneous 97 (5.2%)
ACS, acute coronary syndrome; BNP, B-type natriuretic peptide; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate using the Modification
of Diet in Renal Disease formula; HF, heart failure; IV, intravenous; LVEF, left ventricular ejection fraction; NO, nitric oxide; NSTEMI, non-ST-elevation myocardial infarction;
NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; sGC, soluble guanylate cyclase; STEMI,
ST-elevation myocardial infarction.
creatinine, diabetes, systolic blood pressure, body mass index, HF
duration, chronic obstructive pulmonary disease, male sex, not pre-
scribed a beta-blocker, and not prescribed an angiotensin-converting
enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB).
Baseline characteristics and treatment of patients in VICTORIA are
presented alongside those of the PARADIGM-HF and COMMANDER
HF trials as contemporary HFrEF trials. Values for the PARADIGM-HF
cohort were sourced from the primary publication,7 and then the
baseline characteristics publication10 if not available in the former,
and values for the COMMANDER HF cohort were sourced from the
primary publication.8
All analyses were performed using SAS (version 9.4; SAS Institute
Inc., Cary, NC, USA). The analysis of VICTORIA was based on data
available on 10 June 2019. Final database lock is expected in late
October 2019.
Results
VICTORIA screening and baseline
characteristics
Prior to randomization, a screening period of up to 30 days was
performed, during which confirmation that patients fulfilled the
entry criteria was established. Among 6899 patients who allowed
consent to be screened, 1849 were not randomized; the reasons
for which are summarized in Table 2.
The baseline characteristics of enrolled patients are shown in








































.. three-quarters were male, two-thirds were white, one-half were
Europeans, and one-quarter each from the Asian Pacific region and
the Americas. Two-thirds were enrolled within 3 months of their
index HF hospitalization and equal numbers of the remainder were
either within 3–6 months of hospitalization or within 3 months of
outpatient IV diuretics for worsening HF. Other features consis-
tent with worsening HF were the inclusion of 40% of patients in
NYHA class III and 45% with a history of atrial fibrillation. Dia-
betes and hypertension were frequent, major elevations in either
NT-proBNP or B-type natriuretic peptide (BNP) were present, and
a high MAGGIC risk score of 23.0 was evident at study entry. There
was very good application of background standard of care HF ther-
apy as indicated by high usage of either ACE-I, ARBs or angiotensin
receptor–neprilysin inhibitors (ARNI), beta-blockers and miner-
alocorticoid receptor antagonists: 60% of patients received these
as triple therapy and 15% were on ARNI. There was also a 28%
use of implantable cardioverter-defibrillators (ICDs) and 15% had
a biventricular pacemaker.
VICTORIA patient cohorts
The three patient cohorts – distinguished by their differing index
clinical presentations – are shown in Table 3. Approximately
two-thirds had been hospitalized for HF within the 3 months
prior to their randomization and the other two cohorts were
equally distributed. In general, the baseline characteristics in
these three cohorts were similar although those qualifying based
on IV diuretic use were somewhat older, more often in Latin
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 VICTORIA baseline characteristics and treatments: overall and by index event
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Age (years)
Mean (SD) 67.3 (12.2) 66.8 (12.4) 68.1 (11.8) 68.8 (11.3)
Median (25th–75th percentile) 69.0 (60.0–76.0) 68.0 (59.0–76.0) 69.0 (60.0–77.0) 70.0 (62.0–78.0)
Sex
Male 3842 (76.1%) 2562 (76.1%) 667 (76.6%) 613 (75.4%)
Female 1208 (23.9%) 804 (23.9%) 204 (23.4%) 200 (24.6%)
Race
White 3239 (64.2%) 2103 (62.5%) 567 (65.1%) 569 (70.0%)
Black or African American 249 (4.9%) 169 (5.0%) 65 (7.5%) 15 (1.8%)
Asian 1132 (22.4%) 787 (23.4%) 175 (20.1%) 170 (20.9%)
Native Hawaiian or Pacific Islander 14 (0.3%) 6 (0.2%) 8 (0.9%) 0 (0.0%)
American Indian or Alaskan Native 52 (1.0%) 38 (1.1%) 3 (0.3%) 11 (1.4%)
Multiple 363 (7.2%) 262 (7.8%) 53 (6.1%) 48 (5.9%)
Geographic region
Eastern Europe 1694 (33.5%) 1155 (34.3%) 263 (30.2%) 276 (33.9%)
Western Europe 889 (17.6%) 592 (17.6%) 161 (18.5%) 136 (16.7%)
Asia Pacific 1183 (23.4%) 824 (24.5%) 204 (23.4%) 155 (19.1%)
Latin and South America 724 (14.3%) 460 (13.7%) 108 (12.4%) 156 (19.2%)
North America 560 (11.1%) 335 (10.0%) 135 (15.5%) 90 (11.1%)
BMI (kg/m2)
Median (25th–75th percentile) 26.8 (23.7–30.9) 26.8 (23.7–30.9) 26.6 (23.6–30.5) 27.4 (23.8–30.6)
Ejection fraction recorded at screening (%)
Mean (SD) 28.9 (8.3) 28.4 (8.4) 28.6 (8.2) 31.4 (7.7)
Median (25th–75th percentile) 30.0 (23.0–35.0) 29.0 (22.0–35.0) 29.0 (22.0–35.0) 32.0 (25.0–38.0)
Ejection fraction ≤40% 4670 (92.7%) 3128 (93.1%) 809 (93.4%) 733 (90.2%)
NYHA class at baseline
I 2 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.1%)
II 2967 (58.9%) 1931 (57.5%) 541 (62.8%) 495 (60.9%)
III 2000 (39.7%) 1375 (40.9%) 313 (36.3%) 312 (38.4%)
IV 65 (1.3%) 52 (1.5%) 8 (0.9%) 5 (0.6%)
Medical history
Atrial fibrillation 2269 (45.0%) 1535 (45.6%) 404 (46.5%) 330 (40.6%)
Atrial fibrillation (on the ECG) 1279 (25.3%) 878 (26.1%) 220 (25.3%) 181 (22.3%)
Diabetes mellitus 2377 (47.1%) 1613 (47.9%) 402 (46.3%) 362 (44.5%)
Hypertension 3993 (79.1%) 2664 (79.2%) 700 (80.6%) 629 (77.4%)
Coronary artery disease 2942 (58.3%) 1942 (57.7%) 520 (59.8%) 480 (59.0%)
Stroke 579 (11.5%) 390 (11.6%) 111 (12.8%) 78 (9.6%)
PAD 630 (12.5%) 420 (12.5%) 117 (13.5%) 93 (11.4%)
COPD 863 (17.1%) 574 (17.1%) 147 (16.9%) 142 (17.5%)
Anaemia 1053 (20.9%) 690 (20.5%) 188 (21.6%) 175 (21.5%)
Systolic blood pressure (mmHg)
Mean (SD) 121.3 (15.7) 120.9 (15.7) 122.5 (16.3) 122.1 (15.3)
Median (25th–75th percentile) 119.0 (109.0–131.0) 118.0 (108.0–130.0) 120.0 (109.0–133.0) 120.0 (110.0–132.0)
Diastolic blood pressure (mmHg)
Mean (SD) 72.8 (11.1) 73.0 (11.1) 72.3 (11.2) 72.6 (10.9)
Median (25th–75th percentile) 72.0 (65.0–80.0) 72.0 (65.0–80.0) 72.0 (65.0–80.0) 73.0 (65.0–80.0)
Heart rate (bpm)
Mean (SD) 73.1 (13.1) 73.6 (13.4) 71.9 (12.5) 72.3 (12.2)
Median (25th–75th percentile) 72.0 (64.0–81.0) 72.0 (64.0–82.0) 70.0 (63.0–80.0) 71.0 (64.0–80.0)
Concomitant medications
ACE-I or ARB 3704 (73.5%) 2465 (73.3%) 628 (72.9%) 611 (75.2%)
Beta-blocker 4691 (93.1%) 3119 (92.7%) 813 (94.3%) 759 (93.5%)
MRA 3548 (70.4%) 2442 (72.6%) 579 (67.2%) 527 (64.9%)
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 (Continued)
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ARNI sacubitril/valsartan 731 (14.5%) 484 (14.4%) 137 (15.9%) 110 (13.5%)
Triple therapy (MRA+ beta-
blocker + ACE-I, ARB or ARNI)
3013 (59.8%) 2075 (61.7%) 493 (57.2%) 445 (54.8%)
ICD 1399 (27.8%) 893 (26.5%) 271 (31.4%) 235 (28.9%)
Biventricular pacemaker 739 (14.7%) 461 (13.7%) 158 (18.3%) 120 (14.8%)
Laboratory results
Creatinine (mmol/L)a
Median (25th–75th percentile) 106.0 (80.0–141.0) 106.0 (80.0–141.0) 106.0 (80.0–133.0) 106.0 (80.0–133.0)
eGFR (mL/min/1.73 m2)a
Mean (SD) 61.5 (27.2) 61.1 (27.6) 61.9 (26.5) 62.8 (26.2)
Median (25th–75th percentile) 58.4 (41.2–77.1) 58.0 (39.9–77.0) 58.7 (42.5–76.6) 59.7 (43.8–79.3)
<15 mL/min/1.73m2 12 (0.2%) 10 (0.3%) 0 (0.0%) 2 (0.2%)
15–30 mL/min/1.73m2 494 (10.0%) 348 (10.5%) 83 (9.8%) 63 (7.8%)
>30–60 mL/min/1.73m2 2116 (42.7%) 1408 (42.6%) 363 (42.8%) 345 (42.9%)
>60 mL/min/1.73m2 2333 (47.1%) 1537 (46.5%) 402 (47.4%) 394 (49.0%)
Sodium (mmol/L)
Mean (SD) 139.9 (3.4) 139.8 (3.5) 140.3 (3.1) 140.0 (3.1)
Median (25th–75th percentile) 140.0 (138.0–142.0) 140.0 (138.0–142.0) 141.0 (139.0–142.0) 140.0 (138.0–142.0)
Potassium (mmol/L)
Mean (SD) 4.5 (0.5) 4.5 (0.5) 4.5 (0.5) 4.5 (0.5)
Median (25th–75th percentile) 4.5 (4.2–4.8) 4.5 (4.1–4.8) 4.5 (4.2–4.8) 4.5 (4.2–4.8)
Haemoglobin (g/L)
Mean (SD) 133.9 (19.1) 134.0 (19.4) 132.4 (18.4) 134.8 (18.7)
Median (25th–75th percentile) 134.0 (121.0–147.0) 134.0 (121.0–147.0) 132.0 (120.0–146.0) 136.0 (122.0–148.0)
NT-proBNP at screening (pg/mL)
n 4017 2692 689 636
Median (25th–75th percentile) 3377.0 (1992.0–6380.0) 3848.7 (2177.5–7153.0) 2930.0 (1785.0–4700.0) 2731.5 (1750.5–5067.5)
BNP at screening (pg/mL)
n 1741 1126 329 286
Median (25th–75th percentile) 747.9 (452.4–1340.0) 809.0 (504.4–1465.0) 689.0 (397.0–1172.0) 637.5 (395.0–1018.0)
MAGGIC risk score
n 4658 3086 796 776
Median (25th–75th percentile) 23.0 (18.0–27.0) 23.0 (19.0–27.0) 23.0 (18.0–27.0) 22.0 (18.0–26.0)
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; BNP,
B-type natriuretic peptide (these values used only if NT-proBNP unavailable); COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; eGFR, estimated
glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter-defibrillator; IV, intravenous; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure; MRA,
mineralocorticoid receptor antagonist; NT-proBNP, N-terminal B-type natriuretic peptide; NYHA, New York Heart Association; PAD, peripheral artery disease; SD, standard
deviation.
aAcquired at randomization.
America, and had a trend towards less atrial fibrillation and fewer
co-morbidities. Of particular interest was the gradation in their
entry NP levels across the three cohorts, such that those with a
recent HF hospitalization, i.e. <3 months prior to randomization,
had an approximate 30% higher level of NPs than those with a
longer interval of 3–6 months who were more akin to patients
randomized after recent outpatient IV diuretic therapy. In contrast
to these differences in the differing baseline NPs, the MAGGIC
scores of the patients hospitalized within and beyond 3 months
were similar and those receiving IV diuretics only slightly lower.
Comparison with other HFrEF trials
In Table 4, a comparison of the VICTORIA and the PARADIGM-HF





















.. Note that by contrast to the design of VICTORIA, PARADIGM-HF
included stable HF patients after a run-in period who were both
ACE-I and sacubitril/valsartan tolerant, had a baseline EF of ≤40%,
an eGFR of ≥30 mL/min/1.73 m2 and a minimum BNP of 150 pg/mL
or NT-proBNP of ≥600 pg/mL. As will be evident in comparison to
PARADIGM-HF, the VICTORIA population is somewhat older, had
a higher prevalence of patients with diabetes, hypertension, and a
history of stroke, advanced NYHA class, and greater use of both
ICDs and biventricular pacemakers. By design, in VICTORIA, the
mean eGFR was lower and 10% of subjects had an eGFR between
15 and 30 mL/min/1.73 m2, 14% had and EF between 40% and
45%, and 14.5% were on ARNI at baseline. Of particular note is
the greater than two-fold NT-proBNP entry levels in VICTORIA
which likely reflects, at least in part, the differing entry trial
criteria.
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Age (years)
Mean (SD) 67.3 (12.2) 63.8 (11.4) 66.4
Median (25th–75th percentile) 69.0 (60.0–76.0) – –
Sex
Male 3842 (76.1%) 6565 (78.0%) 3872 (77.1%)
Female 1208 (23.9%) 1832 (22.0%) 1150 (22.9%)
Race
White 3239 (64.2%) 5544 (65.7%) 4128 (82.2%)
Black or African American 249 (4.9%) 428 (5.1%) 65 (1.3%)
Asian 1132 (22.4%) 1509 (17.9%) 727 (14.5%)
Native Hawaiian or Pacific Islander 14 (0.3%) – –
American Indian or Alaskan Native 52 (1.0%) – –
Multiple 363 (7.2%) – –
Other – 918 (11.0%) 102 (2.0%)
Geographic region
Eastern Europe 1694 (33.5%) 2826 (33.5%) 3224 (64.2%)
Western Europe 889 (17.6%) 2051 (24.3%) 458 (9.1%)
Asia Pacific 1183 (23.4%) 1487 (17.6%) 733 (14.6%)
Latin and South America 724 (14.3%) 1433 (17.0%) 458 (9.1%)
North America 560 (11.1%) 602 (7.1%) 149 (3.0%)
Index event
HF hospitalization within 3 months 3366 (66.7%) – –
HF hospitalization 3 to 6 months 871 (17.2%) – –
IV diuretic for HF (without hospitalization) within 3 months 813 (16.1%) – –
BMI (kg/m2)
Mean (SD) 27.8 (5.9) 28.2 (5.5) 27.7 (5.2)
Median (25th–75th percentile) 26.8 (23.7–30.9) – –
Ejection fraction recorded at screening (%)
Mean (SD) 28.9 (8.3) 29.5 (6.2) –
Median (25th–75th percentile) 30.0 (23.0–35.0) – 34.5(27.5–38)
Ejection fraction ≤40% 4670 (92.7%) 8339 (100%) 5122 (100%)
NYHA class at baseline
I 2 (0.0%) 389 (4.7%) 149 (3.0%)
II 2967 (58.9%) 5919 (70.9%) 2218 (44.2%)
III 2000 (39.7%) 2018 (24.1%) 2462 (49.0%)
IV 65 (1.3%) 60 (0.7%) 192 (3.8%)
Medical history
Atrial fibrillation 2269 (45.0%) 3091 (37.0%) 0%
Diabetes mellitus 2377 (47.1%) 2907 (34.9%) 2052 (40.9%)
Hypertension 3993 (79.1%) 5940 (71.2%) 3783 (75.3%)
Coronary artery disease 2942 (58.3%) – 5022 (100%)
Stroke 579 (11.5%) 725 (8.7%) 453 (9.0%)
Systolic blood pressure (mmHg)
Mean (SD) 121.3 (15.7) 121.0 (15.0) –
Median (25th–75th percentile) 119.0 (109.0–131.0) – –
Diastolic blood pressure (mmHg)
Mean (SD) 72.8 (11.1) 74.0 (NA)c –
Median (25th–75th percentile) 72.0 (65.0–80.0) – –
Concomitant medications
ACE-I or ARB 3704 (73.5%) 8339 (100%) 4660 (92.8%)
Beta-blocker 4691 (93.1%) 7811 (93.6%) 4642 (92.4%)
MRA 3548 (70.4%) 4671 (55.3%) 3840 (76.5%)
ARNI sacubitril/valsartan 731 (14.5%) – –
Triple therapy (MRA+ beta- blocker + ACE-I or ARB or ARNI) 3013 (59.8%) – –
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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ICD 1399 (27.8%) 1243 (14.9%) 438 (8.7%)
Biventricular pacemaker 739 (14.7%) 574 (6.8%) 222 (4.4%)
Laboratory results
Creatinine (mmol/L)b
Mean (SD) 116.9 (49.8) 99.0 (NA)c –
Median (25th–75th percentile) 106.0 (80.0–141.0) – –
eGFR (mL/min/1.73 m2)b
Mean (SD) 61.5 (27.2) 68.0 (NA)c –
Median (25th–75th percentile) 58.4 (41.2–77.1) – –
15–30 mL/min/1.73m2 494 (10.0%) – 163 (3.2%)
NT-proBNP at screening (pg/mL)
n 4017 – –
Median (25th–75th percentile) 3377.0 (1992.0–6380.0) 1608.0 (886.0–3221.0) 2870.0 (1528.0–6332.0)
BNP at screening (pg/mL)
n 1741 – –
Median (25th–75th percentile) 747.9 (452.4–1340.0) 253.0 (154.0–470.0)d 698.8 (392.0–1252.0)
MAGGIC risk scoree
n 4658 8375e –
Median (25th–75th percentile) 23.0(18.0–27.0) 20.0(16.0–24.0) –
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; BNP, B-type
natriuretic peptide (these values used only if NT-proBNP unavailable); eGFR, estimated glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter-defibrillator;
IV, intravenous; MRA, mineralocorticoid receptor antagonist; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure; NA, not available; NT-proBNP, N-terminal
pro-B-type natriuretic peptide; NYHA, New York Heart Association; SD, standard deviation.
aApproximated from reference.8
bAcquired at randomization.
cAs reported in reference.9
dApproximated from reference.7
eAdapted as per PARADIGM-HF score where 1 point ≥1 year for HF duration.
The differences in the background risk of the two populations
are especially evident given the substantially greater median
MAGGIC risk score (adapted to align with the PARADIGM-HF
calculation) in VICTORIA of 23 [interquartile range (IQR)
18–27] as opposed to the score of 20 (IQR 16–24) found in
PARADIGM-HF.11
Also represented in Table 4 is COMMANDER HF which, by
design, randomized patients with HFrEF and a presumed ischaemic
aetiology in whom atrial fibrillation was excluded and who had
been treated for an episode of worsening HF (i.e. their index event)
within the previous 21 days. VICTORIA patients were slightly older,
had less patients in advanced NYHA class III and IV, more with both
renal dysfunction and a lower EF and higher NT-proBNP and BNP
levels at study entry.
There was considerably greater use of both ICDs and biventric-
ular pacemakers in VICTORIA than in the other two trials.
Discussion
VICTORIA represents a large and well-characterized population
of HFrEF patients who at the time of study entry had shown
symptomatic deterioration despite optimal background standard
of care HF therapy. Overall, the population has high predicted
risk on optimal background medical therapy as compared with





































. that at least 782 CEC-confirmed CV deaths and more than 1561
patients have experienced a composite primary endpoint: we are
thus assured of adequate power to address the primary study
hypothesis.
The timely enrolment of these patients suggests that this medi-
cally challenging high-risk population continues to exist in substan-
tial numbers worldwide despite good background standard of care
therapy, and represents a key underserved cohort that deserves
future study as noted previously.1
Several unique features set the current study apart from prior
work, including the absence of a run-in period, broader inclu-
sion criteria and three differing cohorts based on the symptomatic
nature of their index HF worsening events. These subsets describe
how previously chronic stable HF patients evolve after a recent
exacerbation that requires either hospitalization or acute medical
outpatient intervention with IV diuretics. Other novel aspects wor-
thy of note are the 369 patients with an EF between 41% and 45%,
the 494 patients with an eGFR between 15 and 30 mL/min/1.73 m2
and the 14.5% (n = 731) who received ARNI: analysis of the
outcomes of these ‘mid-range’ EF, impaired renal function and
ARNI-treated patient subsets will be of particular interest.
Examination of Table 3 highlights the distinctive characteris-
tics of the three pre-defined HFrEF subsets based on their index
presentation and underscores that those patients who present
within 3 months of a prior hospitalization portend the highest
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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potential future risk as denoted by their more than 30% increased
NT-proBNP than those with worsened symptoms presenting
within 3–6 months after hospitalization or those presenting for
outpatient administration of IV diuretics. Interestingly however, this
finding did not translate into differences in their MAGGIC risk
scores. The GISSI-HF (Gruppo Italiano per lo Studio della Soprav-
vivenza nell’Insufficienza Cardiaca-Heart Failure) investigators have
recently reflected on the lack of accuracy of the MAGGIC score
in capturing the risk of sudden cardiac death in HFrEF patients and
called for new prognostic tools in this population.14 These new data
from VICTORIA should be ultimately helpful in further informing
the spectrum of CV risk in HF, as well as the response to therapy
and the design of future HFrEF trials.
The PARADIGM-HF trial defined a new standard of care therapy
for patients with stable HFrEF who tolerate ACE-I and ARNI
therapy. It is noteworthy – but not surprising – given the differing
aforementioned differences in entry criteria, that PARADIGM-HF
patients have a substantially lower MAGGIC risk score than the
current VICTORIA study population.
Conclusion
In conclusion, VICTORIA enrolled a large international high-risk
population of worsening chronic HFrEF despite optimal standard
of HF therapy. As compared to prior large chronic HFrEF trials, NP
levels at entry were higher and reflect not only three common, yet
distinctive, clinical presentation streams, but also inclusion of novel
subsets with mid-range EF, reduced renal function and baseline
ARNI therapy, attesting to the broad contemporary generalizability
of the trial. VICTORIA is well positioned to establish the role of
vericiguat, a new sGC stimulator in the management of HFrEF.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Appendix S1. VICTORIA Study Group.
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